Feminist Activism in the Context of Clinical Trials and Drug Roll-Out
Document Type
Book Chapter
Publication Date
2020
Editor(s)
Chris Dietz, Mitchell Travis, and Michael Thomson
ISSN
2947-9274
ISBN
978-3-030-42199-1
Publisher
Palgrave Macmillan Cham
Language
en-US
Abstract
In 2006, the Food and Drug Administration (FDA) approved Gardasil, a Human Papilloma Virus (HPV) vaccine, for the purposes of stopping the spread of HPV, a primary cause of cervical cancer. While its development and approval were largely seen as necessary steps forward for women’s health, feminist movements in both the United States and India took a critical posture toward the vaccine. Their reactions derived from a shared skepticism of how knowledge is produced and diffused by federal agencies and pharmaceutical companies about women’s bodies. Using the HPV vaccine as an example, this chapter examines the role of feminists in bioethical debates about the production of knowledge about women’s bodies and the politics of vaccine roll-out.
Recommended Citation
Aziza Ahmed,
Feminist Activism in the Context of Clinical Trials and Drug Roll-Out
,
in
A Jurisprudence of the Body
205
(Chris Dietz, Mitchell Travis, and Michael Thomson ed.,
2020).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/3353
